{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:23:07Z","timestamp":1779297787667,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Children with chest wall Ewing sarcoma with malignant pulmonary effusion or pleural stranding require hemithorax radiation, often with plans that exceed lung constraints. We investigated disease control and pneumonitis in children requiring hemithorax radiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Eleven children (median age 13\u00a0years) received hemithorax radiotherapy. Symptomatic radiation pneumonitis was considered National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade 1+ with respiratory symptoms. Mean lung dose (MLD), volume of lung exposed to a dose \u22655\u00a0Gy (V5), \u226520\u00a0Gy (V20), and \u226535\u00a0Gy (V35) were recorded. Adult and pediatric lung constraints were obtained from Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines and Children's Oncology Group (COG) protocols, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median hemithorax dose was 15\u00a0Gy (1.5\u00a0Gy\/fraction). Median total dose was 51\u00a0Gy (1.8\u00a0Gy\/fraction). Most plans delivered both protons and photons. The ipsilateral MLD, V5, and V20 were 27.2\u00a0Gy, 100%, and 48.3%; the bilateral MLD, V20, and V35 were 14.1\u00a0Gy, 22.8%, and 14.3%, respectively. One hundred percent, 36%, and 91% of treatments exceeded recommended adult ipsilateral lung constraints of V5 &lt;65%, V20 &lt;52%, and MLD of 22\u00a0Gy; 64%, 45%, and 82% exceeded COG bilateral lung constraints of V20 &lt;20%, MLD &lt;15\u00a0Gy, and MLD &lt;12\u00a0Gy, respectively; 82% of treatments exceeded the COG ipsilateral lung constraint of V20 &lt;30%. At a median 36\u00a0months (range 12\u2013129), the symptomatic radiation pneumonitis incidence was 0%. Two patients progressed with nonpulmonary metastatic disease and died at a median 12\u00a0months following radiotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Existing guidelines may overestimate pneumonitis risk, even among young children receiving multiagent chemotherapy. For children with chest wall Ewing sarcoma and other thoracic malignancies, more data are needed to refine pediatric dose\u2013effect models for pulmonary toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.29287","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T14:30:09Z","timestamp":1629124209000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary dose tolerance in hemithorax radiotherapy for Ewing sarcoma of the chest wall: Are we overestimating the risk of radiation pneumonitis?"],"prefix":"10.1002","volume":"68","author":[{"given":"Akash D.","family":"Parekh","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology University of Florida College of Medicine  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-1873","authenticated-orcid":false,"given":"Daniel J.","family":"Indelicato","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Florida College of Medicine  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-034X","authenticated-orcid":false,"given":"Raymond B. Mailhot","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Florida College of Medicine  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronny L.","family":"Rotondo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Kansas School of Medicine  Kansas City Kansas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7581-4605","authenticated-orcid":false,"given":"Julie A.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Florida College of Medicine  Jacksonville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1709"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2017.04.015"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.01.007"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.04.037"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2009.09.001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.04.043"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.030"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1378"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.03.005"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03986-X"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.03.063"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.091"},{"key":"e_1_2_8_14_1","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.U.S. Department of Health and Human Services. May 28 2009(v4.03: June 14 2010). Accessed June 25 2021.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201006\u201014_QuickReference_5x7.pdf"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.01.036"},{"key":"e_1_2_8_16_1","volume-title":"AEWS1031: a phase III randomized trial of adding vincristine\u2010topotecan\u2010cyclophosphamide to standard chemotherapy in initial treatment of non\u2010metastatic Ewing sarcoma","author":"Children's Oncology Group"},{"key":"e_1_2_8_17_1","unstructured":"AHOD1331: a randomized phase 3 study of brentuximab vedotin (SGN\u201035 IND #117117) for newly diagnosed high\u2010risk classical Hodgkin lymphoma (cHL) in children and young adults.Children's Oncology Group.https:\/\/www.childrensoncologygroup.org\/ahod1331. Accessed February 2 2020."},{"key":"e_1_2_8_18_1","unstructured":"ARST1431: a randomized phase 3 study of vincristine dactinomycin cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC\/VI plus temsirolimus (TORI Torisel NSC# 683864) in patients with intermediate risk (IR) rhabdomyosarcom.Children's Oncology Group.https:\/\/www.childrensoncologygroup.org\/arst1431. Accessed February 2 2020."},{"key":"e_1_2_8_19_1","unstructured":"ANBL1531: a phase 3 study of 131I\u2010metaiodobenzylguanidine (131I\u2010MIBG) or crizotinib added to standard therapy for children with newly diagnosed high\u2010risk neuroblastoma.Children's Oncology Group.https:\/\/www.childrensoncologygroup.org\/anbl1531. Accessed February 2 2020."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.126503"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.03.026"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20660"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.04.066"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197406)33:6<1520::AID-CNCR2820330608>3.0.CO;2-V"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.05.036"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.08.034"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.04.001"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01685-6"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.027"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.08.343"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.026"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2675"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.08.056"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.10.002"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21175"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20457"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:41:50Z","timestamp":1693284110000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/pbc.29287"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29287","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"2021-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29287"}}